Allena Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Allena Pharmaceuticals generated cash of -$45,678,000, which is less than the previous year. Cash used in financing activities reached the amount of $41,291,000 last year. Net change in cash is therefore -$5,054,000.
Cash Flow
| 2015 | -13.17M | 5K | 55.29M |
|---|---|---|---|
| 2016 | -23.39M | -23.76M | 3.39M |
| 2017 | -21.06M | 23.41M | 66.89M |
| 2018 | -31.83M | -318K | -694K |
| 2019 | -43.63M | -122K | 12.11M |
| 2020 | -28.15M | -632K | 33.82M |
| 2021 | -45.67M | -667K | 41.29M |
ALNA Cash Flow Statement (2015 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 35.04M | 30.00M | 61.64M | 94.49M | 25.25M | 69.01M | 26.88M |
Operating activities | |||||||
Net income | -32.84M | -32.84M | -47.33M | -35.64M | -21.65M | -24.50M | -14.24M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 363K | 166K | 163K | 78K | 73K | 46K | 98K |
Stock-based compensation expense | 3.67M | 4.05M | 2.98M | 2.04M | 517K | 251K | 207K |
| Deferred income tax benefit | 3.67M | 4.05M | 2.98M | 2.04M | 517K | 251K | 207K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -1.37M | -544K | 972K | 441K | 199K | -525K | 1.00M |
Cash generated by operating activities | -45.67M | -28.15M | -43.63M | -31.83M | -21.06M | -23.39M | -13.17M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -1.24M | -53.21M | 0 |
Investments In Property Plant And Equipment | -667K | -650K | -122K | -318K | -57K | -102K | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -667K | -632K | -122K | -318K | 23.41M | -23.76M | 5K |
Financing activities | |||||||
Common Stock Issued | 41.27M | 33.99M | 0 | 34K | 67.19M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -309K | 0 | 0 | 0 |
Repayments of term debt | 0 | -10M | 0 | -10.49M | 0 | -6.25M | 0 |
Cash used in financing activities | 41.29M | 33.82M | 12.11M | -694K | 66.89M | 3.39M | 55.29M |
Net Change In Cash | -5.05M | 5.03M | -31.63M | -32.85M | 69.24M | -43.76M | 42.12M |
Cash at end of period | 29.98M | 35.04M | 30.00M | 61.64M | 94.49M | 25.25M | 69.01M |
| Data source | Data source | Data source | Data source | Data source |